During a conference at the headquarters of the Polish Security Printing Works, the head of the MIAA stressed that this is one of the largest transactions that has taken place in recent years. “We are launching a new strategic investment for the Polish state and its citizens. In this way we protect the next generations of Poles, so that every citizen can have certainty of access to the Polish currency, to cash. We are living in difficult times. Hacking attacks or technical interruptions cannot undermine this certainty," he added.

Minister Mariusz Kaminski also pointed out that today's event is another step towards strengthening the security of our country. He added that the signing of the contract between the two state-owned companies was a guarantee of stable access to cash for Poles and an assurance of drug safety. “I would like to thank the President of PWPW and the President of Polfa Tarchomin, but also the Ministry of State Assets for their excellent, reliable cooperation in the implementation of this contract” - concluded the head of the Ministry of Internal Affairs and Administration.

In turn, the deputy minister of state assets said that Polfa Tarchomin will use the funds from the land sale to complete the construction of a plant manufacturing oncology drugs. “Polfa Tarchomin secures the needs of Poles in terms of medicines. For its 200th anniversary Poland's largest producer of antibiotics, Poland's first producer of insulin - is finalising the construction of an oncology drugs factory. The first such drugs factory in Poland and the most modern in our part of Europe, or actually the Centre for Development and Production of Oncological Drugs, is being built in Tarchomin, Warsaw, and is nearing completion, the Deputy Minister of State Assets stressed.

The briefing was also attended by Piotr Ciompa, CEO of PWPW, and Jarosław Król, CEO of TZF Polfa S.A.

Contract between PWPW S.A. and TZF Polfa S.A.

For PWPW, the purchase of a plot of land in Warsaw's Tarchomin is the implementation of a long-term strategic plan and a need resulting from the limitations of the plant's current location in the Nowe Miasto in Warsaw. The company's current premises already use 100 per cent of its office, production, and warehousing space. In addition, the almost 100-year-old buildings tend to be a barrier to the introduction of modern production equipment and involve the need to demolish external walls and rebuild them after the installation of machinery. Added to this is the lack of expansion possibilities and limited redevelopment opportunities due to conservation requirements. Not without significance is also the fact that PWPW's paper and printing production is located in the city centre, which increases production costs and entails serious logistical difficulties.

For TZF Polfa S.A, the sale of the plot of land, which is not used by the company, will allow it to pursue its main goal of producing oncology drugs. Polfa is strongly betting on the manufacturing of anticancer drugs used, among others, in the treatment of breast cancer, acute leukaemia or multiple myeloma, as well as injectable antibiotics and other highly active drugs used in the treatment of fungal diseases, in rheumatology and in anaesthesiology. The transaction will make it possible to complete the construction of the largest plant producing these types of drugs in Poland and our part of Europe. The target production capacity of both lines is more than 20 million vials and 6 million ampoules per year.

By the end of the year, TZF Polfa plans to obtain the occupancy permit for the new factory. The production of the ordered modern machines that are to constitute the production equipment is already underway. The launch of the first Oncology Drug Development and Production Centre in Poland and in our region is planned for 2024-2025.